SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID Apr 21, 2017
SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Apr 12, 2017
SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request Mar 2, 2017
SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors Jan 26, 2017
SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections Dec 13, 2016
SCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference Dec 12, 2016
